FIELD: medicine.
SUBSTANCE: invention can be used to treat renal cell carcinoma (RCC). The method of the invention comprises administering to a mammal with RCC an effective amount of sunitinib and an ALK1 polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1.
EFFECT: use of the invention can slow the growth of the tumor and increase the activity of sunitinib.
10 cl, 20 dwg, 15 ex
Authors
Dates
2017-10-16—Published
2013-02-01—Filed